Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
palomid 529
- Development stage
- Phase 1
- Lead developer
- Paloma Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral, Subconjunctival Injection, Subcutaneous
01
Overview
Palomid 529 is a small molecule inhibitor that targets the PI3K/AKT/mTOR signaling pathway by dissociating both mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). It is a derivative of a non-steroidal estrogen antagonist but lacks estrogen receptor binding activity. Palomid 529 exhibits antiangiogenic and anticancer properties by inhibiting tumor growth, angiogenesis, and vascular permeability. The drug has been investigated primarily for oncology indications such as glioblastoma (where it has received orphan designation in the US) and prostate cancer, as well as ophthalmology indications like neovascular age-related macular degeneration (AMD), particularly in patients refractory to anti-VEGF therapy. It penetrates the blood-brain barrier in animal models[1][2][3][4][5][8].
- Other names
- RES-529RES529RES 529
02
Targets
Mechanistic target of rapamycin complex 1Mechanistic target of rapamycin kinase complex 2
Beyond the preview
Go deeper on palomid 529.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on palomid 529.